Informed Consent
Item
1. written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
2. ≥18 years of age
boolean
C0001779 (UMLS CUI [1])
Liver carcinoma
Item
3. diagnosis of hcc
boolean
C2239176 (UMLS CUI [1])
Liver carcinoma Advanced Locally
Item
4. locally advanced hcc
boolean
C2239176 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
Liver function Preserved
Item
5. preserved liver function
boolean
C0232741 (UMLS CUI [1,1])
C0033085 (UMLS CUI [1,2])
ECOG performance status
Item
6. eastern cooperative oncology group 0 or 1
boolean
C1520224 (UMLS CUI [1])
Disease Spread Extrahepatic
Item
1. presence of extra-hepatic spread of disease.
boolean
C0012634 (UMLS CUI [1,1])
C0332261 (UMLS CUI [1,2])
C1517058 (UMLS CUI [1,3])
Tumor Vascular Invasion Branch of portal vein | Tumor Vascular Invasion Main portal vein
Item
2. macrovascular invasion of lobar portal vein branches or main portal vein.
boolean
C0521157 (UMLS CUI [1,1])
C0226736 (UMLS CUI [1,2])
C0521157 (UMLS CUI [2,1])
C1183135 (UMLS CUI [2,2])
Patient Eligible Excision | Patient Eligible Transplantation | Patient Eligible Ablation
Item
3. candidate for surgical resection, transplantation, or local ablation.
boolean
C0030705 (UMLS CUI [1,1])
C1548635 (UMLS CUI [1,2])
C0728940 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C1548635 (UMLS CUI [2,2])
C0040732 (UMLS CUI [2,3])
C0030705 (UMLS CUI [3,1])
C1548635 (UMLS CUI [3,2])
C0547070 (UMLS CUI [3,3])
Intra-arterial Embolization Liver carcinoma | Chemotherapy Liver carcinoma | Systemic therapy Liver carcinoma
Item
4. prior intra-arterial embolization, chemotherapy or systemic therapy for hcc.
boolean
C0013931 (UMLS CUI [1,1])
C0694634 (UMLS CUI [1,2])
C2239176 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2,1])
C2239176 (UMLS CUI [2,2])
C1515119 (UMLS CUI [3,1])
C2239176 (UMLS CUI [3,2])
Medical contraindication TACE
Item
5. any contraindication for tace.
boolean
C1301624 (UMLS CUI [1,1])
C3539919 (UMLS CUI [1,2])
Platelet Count measurement | International Normalized Ratio
Item
6. platelet count <50,000/mm3 or international normalized ratio >1.5.
boolean
C0032181 (UMLS CUI [1])
C0525032 (UMLS CUI [2])
Anthracycline Antibiotics | Doxorubicin | sorafenib
Item
7. previous treatment with anthracycline antibiotics (e.g. doxorubicin) or sorafenib.
boolean
C0003234 (UMLS CUI [1])
C0013089 (UMLS CUI [2])
C1516119 (UMLS CUI [3])
Coronary Artery Disease Unstable | Myocardial Infarction
Item
8. unstable coronary artery disease or recent myocardial infarct (i.e. within 1 year).
boolean
C1956346 (UMLS CUI [1,1])
C0443343 (UMLS CUI [1,2])
C0027051 (UMLS CUI [2])
Cardiac ejection fraction
Item
9. known ejection fraction < 50%.
boolean
C0232174 (UMLS CUI [1])
Communicable Diseases Requirement Antibiotic therapy
Item
10. current infections requiring antibiotic therapy.
boolean
C0009450 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0338237 (UMLS CUI [1,3])
Blood Coagulation Disorders
Item
11. suffering from a known bleeding disorder.
boolean
C0005779 (UMLS CUI [1])
Renal Insufficiency | Creatinine measurement, serum
Item
12. renal insufficiency (serum creatinine > 2 mg/dl).
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Aspartate aminotransferase increased | Alanine aminotransferase increased
Item
13. aspartate aminotransferase and/or alanine transaminase >5 times upper limit of normal.
boolean
C0151904 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
Liver disease Advanced
Item
14. presence of advanced liver disease.
boolean
C0023895 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
Medical contraindication Doxorubicin
Item
15. any contraindication for doxorubicin administration:
boolean
C1301624 (UMLS CUI [1,1])
C0013089 (UMLS CUI [1,2])
Comorbidity Protocol Compliance Poor | Social situation Protocol Compliance Poor | Comorbidity compromises Patient safety | Social situation compromises Patient safety
Item
16. any co-morbid condition or social situation, which has a high likelihood of causing poor compliance with the study protocol or jeopardizes the patient's safety.
boolean
C0009488 (UMLS CUI [1,1])
C0525058 (UMLS CUI [1,2])
C0542537 (UMLS CUI [1,3])
C0748872 (UMLS CUI [2,1])
C0525058 (UMLS CUI [2,2])
C0542537 (UMLS CUI [2,3])
C0009488 (UMLS CUI [3,1])
C2945640 (UMLS CUI [3,2])
C1113679 (UMLS CUI [3,3])
C0748872 (UMLS CUI [4,1])
C2945640 (UMLS CUI [4,2])
C1113679 (UMLS CUI [4,3])
Second Primary Cancer | Exception Basal cell carcinoma | Exception Superficial carcinoma of urinary bladder | Exception Malignant melanoma in situ | Exception Prostate carcinoma Treated | Exception Disease Free of
Item
17. patient has another primary tumor, with the exception of conventional basal cell carcinoma, superficial bladder cancer, melanoma in situ, or treated prostate cancer currently without biochemical or radiographic evidence of active disease
boolean
C0751623 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1336527 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0854696 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0600139 (UMLS CUI [5,2])
C1522326 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0012634 (UMLS CUI [6,2])
C0332296 (UMLS CUI [6,3])
Study Subject Participation Status | Investigational Medical Device | Investigational New Drugs
Item
18. participation in a clinical trial of an investigational device or drug within 4 weeks of study entry.
boolean
C2348568 (UMLS CUI [1])
C2346570 (UMLS CUI [2])
C0013230 (UMLS CUI [3])
Pregnancy | Breast Feeding
Item
19. pregnant or breast-feeding patients.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])